Prevention and treatment of bronchial asthma.doc

 PAGE \* MERGEFORMAT 11 Prevention and treatment of bronchial asthma Bronchial asthma (hereinafter referred to as asthma) by eosinophils, mast cells and T lymphocytes and other inflammatory cells involved in chronic inflammation of the airway. This inflammation so susceptible to various stimulating factors have airway hyper-reactivity, and can lead to airway narrowing, expressed as repeated episodes of wheezing, difficulty breathing, chest tightness or coughing and other symptoms. As people with asthma continued to deepen understanding of the disease, treatment focus has shifted from mere mitigation of airway smooth muscle spasm, to the prevention, control airway inflammation-based comprehensive treatment. 1, bronchial asthma medication Recent 1, Theophylline Theophylline is a commonly used class of asthma drugs, the application has been for over 50 years. Theophylline belongs to yellow fat derivatives in recent years, many studies have shown that, in addition to the direct smooth muscle relaxation, but also has anti-inflammatory effects, specifically manifested as follows: First, suppress IgE-mediated mast cell release of histamine, by increasing the body addicted Acid granulocytes and mast cell cyclic adenosine monophosphate (cAMP) concentration and inhibit its release; Secondly, can reduce the respiratory tract in bronchial asthma need who interleukin 4 (IL-4) and interleukin-5 (IL-5) to influence the content of arachidonic acid metabolism, so that eosinophils release of leukotriene reduced by about 61%; third, theophylline could inhibit neutrophil adhesion capillary wall, and further inhibit their travel out of the capillary blood vessels play a role in phagocytosis, while able to enhance monocyte - macrophage chemotactic effect, due to asthma results are obvious, is one of the clinical drug of choice, currently used are aminophylline, gasping for breath, cough tablets Dingchuan and theophylline sustained-release tablets, controlled-release tablets and s